COVID-19 Vaccine Commercialization Will Be Costly for U.S. Health System
COVID-19 vaccines could add billions of dollars to overall health care spending each year if the federal government’s purchasing program ends early next year, according to a Kaiser Family Foundation analysis. To date, the federal government has spent about $25 billion on purchasing Pfizer and Moderna COVID-19 vaccines combined, at a weighted average purchase price of $20.69 per dose.
Pfizer and Moderna both announced that the average commercial price per dose for their vaccines could be three to four times greater than the price paid by the government, between $82 and $130 per dose. If half of U.S. adults receive a booster shot at the expected commercial prices, it could cost between $3.7 billion and $14.8 billion to purchase enough doses for the group (129 million).
Related Posts

End of Government Purchasing, PHE Could Lead to Access, Pricing Issues for COVID Treatments
READ MORE
Insurers Brace for When U.S. Stops Buying COVID-19 Vaccines, Therapeutics
READ MORE